Search PubMed⌕ Search

Biomedical subjects

B Bean

Publications and source records attributed to B Bean.

At least 37 records · Page 2Linked to original sources

Cephalothin clearance of Staphylococcus aureus from two experimental infection sites in the presence and absence of local phagocytic cells.

The clearance of Staphylococcus aureus from perforated peritoneal capsules which are accessible to phagocytic cells, and subcutaneous Visking chambers which exclude phagocytes, was studied simultaneously in eight rabbits implanted with both devices. Animals were treated with cephalothin, 100 mg/kg im every 8 h for sixteen doses, beginning 24 h after inoculation of the infection sites with S. aureus (cephalothin MIC 0.125 mg/l, MBC 0.5 mg/l). At the start of cephalothin, subcutaneous chambers contained a higher concentration of S. aureus (8.4 log10 cfu/ml) than peritoneal capsules (6.8 log10 cfu/ml, P less than 0.001). There was a significant bactericidal effect in subcutaneous chambers on both the third and sixth day of treatment (P less than 0.002), whereas in peritoneal capsules this did not occur until day six. The total reduction in bacterial count in subcutaneous chambers (7.0 log10 cfu/ml) was significantly greater than in capsules (4.4 log10 cfu/ml, P less than 0.002). The mean concentration of cephalothin in subcutaneous chambers (10.7 mg/l) was significantly higher than in peritoneal capsules (6.1 mg/l, P less than 0.02), but no difference in in-vitro killing of S. aureus was detected at these concentrations. We conclude that cephalothin clearance of S. aureus from a site accessible to phagocytes was delayed when compared to a phagocyte-inaccessible site.

Animals↗

Treatment of varicella-zoster virus infections.

Effective antiviral therapy is now available for many forms of infection due to varicella-zoster virus. Acyclovir is the most widely prescribed treatment, but the virus is not exquisitely sensitive to this drug, and others are under study. The goals of therapy differ among different kinds of patients and must be considered when designing a treatment program.

Acyclovir↗

Semen fertility--an evaluation system for artificial insemination sires, technicians, herds, and systematic fixed effects.

Semen fertility was evaluated on 4478 artificial insemination bulls using 2,007,520 breeding receipts for inseminations to 397,979 Holstein cows between January 1, 1978 and November 1, 1984 using mixed linear model methodology. Bulls differed on average by +/- 3.68% conception. Differences between herd-years ranged from 27.4 to -32.3% conception with an average difference of +/- 8.33%. Within herds, cow parity-service number accounted for the largest variation, ranging from 24.0% to -18.5% conception. June was the best month for conception (1.9) and January the poorest (-2.3), indicating effect of temperature and confinement in winter on estrous detection in the northeastern United States. Cows with intervals between repeat services of 21 d had conception rates 12% higher than intervals between repeat services of 11 d. Effect of month-year of semen collection varied by +/- 1.33% conception. Differences between technicians within years varied by +/- 3.37%. Results of the analysis indicate improved conception on dairy farms can be achieved by improved estrous detection, which is a major component of herd-year and service interval. Other components of the model contributed little to the variance in conception or are uncontrollable by farm management.

Animals↗

Systematic environmental, direct, and service sire effects on conception rate in artificially inseminated Holstein cows.

Result of insemination was verified for 329,314 artificial inseminations by 882 service sires to 97,245 Holstein cows in 1,075 herds between May 1970 and December 1983. Estimates of systematic environmental and genetic components of cow and service sire components of conception rate were obtained preliminary to development of a fertility monitoring system. Conception rate was 2.9% higher in stanchion than loose housed herds and 2.3% higher in grade than registered cows. Fall months were superior to winter months, the greatest difference being 6.1% between October and January. Conception rate increased with herd milk production, decreased with both increased cow age, and increased herd size in mature and old cows. Regions and inseminators within regions were highly variable. Conception may be influenced by semen price; however, week day of insemination and duration of semen storage had no effect. Conception rate decreased for semen by bulls 8 yr and older, was lowest for semen harvested in June, but no season of collection effect was detected. No genetic trends for cow and service sire conception rate were found; heritability and repeatability were .08 and .06, respectively. Genetic correlations between cow and service sire conception rate and these components with first lactation production and semen output measures were all near zero. Therefore, the relationship between sire fertility and daughter fertility is near zero.

Animals↗

The contribution of echocardiography to the community practice of cardiology. A prospective study.

The utility of echocardiography in a clinical office practice was assessed by prospectively studying 93 patients. Each patient was examined by a cardiologist and a diagnosis and management plan was outlined. An M-mode and 2D echocardiogram was then obtained and interpreted by a second cardiologist without knowledge of the clinical findings. Patients were then categorized as follows: group 1, clinical and echo diagnosis agree, management unchanged (67 patients); group 2, clinical and echo diagnosis agree, management changed (two patients); group 3, clinical and echo diagnosis disagree, management unchanged (16 patients); and group 4, clinical and echo diagnosis disagree, management changed (eight patients). Echocardiography significantly altered management of 11 percent of patients, provided additional important information in 48 percent, and confirmed the clinical impression in 74 percent of patients. It was particularly helpful in determining left ventricular structure and function, valvular anatomy, and in the diagnosis of clinically unsuspected idiopathic hypertrophic subaortic stenosis.

Adolescent↗

Acyclovir halts progression of herpes zoster in immunocompromised patients.

We conducted a placebo-controlled, double-blind study of acyclovir therapy for acute herpes zoster in immunocompromised patients. Of the 94 patients enrolled in the study, 52 had localized skin lesions at entry, and 42 had disseminated cutaneous zoster. A one-week course of intravenous acyclovir (1500 mg per square meter of body-surface area per day) halted progression of zoster in both groups, as determined by development or progression of cutaneous dissemination, development of visceral zoster, or proportion of cases deemed treatment failures. Significantly fewer patients treated with acyclovir within the first three days after the onset of exanthem had complications of zoster, as compared with patients treated with placebo (P = 0.02 by Fisher's exact test), but acyclovir also stopped progression of zoster in patients treated after three days of rash (P = 0.05 by Fisher's exact test). Acyclovir recipients with disseminated cutaneous zoster had a significantly accelerated rate of clearance of virus from vesicles, as compared with placebo recipients (P = 0.05 by the Breslow test).

Acyclovir↗

Influenza B: hospital activity during a community epidemic.

During a community epidemic of influenza B, surveillance throat cultures for influenza were collected from febrile adult patients and hospital employees on three medical wards to determine the frequency and source of influenza among hospitalized patients. Twenty-five cases of influenza B (18.5% of febrile patients) were identified; no clusters of influenza-like illness occurred. The attack rate on two wards was 4.6%. Peak hospital influenza incidence followed that in the community by 1-2 weeks. Twelve of the cases were community-acquired and 13 were nosocomial. 75% of community-acquired cases had three or more common influenza B symptoms, compared with only 39% of nosocomial cases. A viral etiology of fever was suspected clinically in one-half of the cases, but influenza was specifically suspected in only one case. Two ill culture-positive nurses were identified on the job but no asymptomatic carriers were found among ward personnel. We conclude that influenza B cases were present among hospitalized patients in the absence of recognizable clusters of disease and that patients with community-acquired illness as well as nursing personnel may have introduced influenza into the hospital. Influenza B may be difficult to diagnose clinically in hospitalized patients, but viral throat cultures performed in all suspected cases should identify many infected patients.

Adult↗

Acyclovir in shingles.

Acyclovir given intravenously in either low dose (5 mg/kg every 8 h) or high dose (500 mg/m2 every 8 h) significantly reduced pain and accelerated skin healing in acute herpes zoster occurring in otherwise healthy adults. The higher dose also significantly reduced the duration of viral shedding. No significant effect on post-herpetic neuralgia could be demonstrated, although the higher dose showed a promising trend. No adverse effects were associated with the lower dose, but acyclovir at 500 mg/m2 resulted in nausea, vomiting and transiently elevated serum creatinine in a substantial number of patients.

Acyclovir↗

Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients.

In a randomized, placebo-controlled, double-blind trial of intravenous acyclovir in the treatment of varicella zoster virus (VZV) infections, 8 of 20 immunocompromised children with varicella received acyclovir (500 mg/m2/dose three times daily for 7 days). There was no significant difference in skin healing between the acyclovir and placebo groups although there was a significant reduction in the incidence of development of pulmonary involvement during acyclovir treatment. Nineteen out of 34 patients received vidarabine (10 mg/kg/day for 5 days). Vidarabine significantly shortened the duration of new vesicle formation. Both drugs significantly reduced the incidence of visceral varicella, the most serious complication of VZV infection. An open trial also concluded that early treatment of varicella in these patients is essential. Of the 94 patients with zoster infection, 52 received acyclovir (500 mg/m2/dose infused over one hour three times daily for 7 days). Acyclovir recipients healed more rapidly, had fewer days of pain and shorter duration of viral shedding compared with placebo patients. The most important finding was that acyclovir significantly protected against progression of zoster as defined by development or progression of cutaneous dissemination and development of visceral zoster. Vidarabine seemed to be equally effective in this respect. The likelihood of cutaneous dissemination is related to the nature of the underlying condition. The in vitro sensitivity of VZV isolates from patients with second episode VZV infection during the trial did not change appreciably which suggests that VZV does not become resistant to acyclovir during therapy.

Acyclovir↗

Acyclovir therapy for acute herpes zoster.

31 adults took part in a randomised, placebo-controlled, double-blind trial of intravenous acyclovir therapy (500 mg/m2 intravenously 3 times daily for 5 days) for acute herpes zoster. Acyclovir reduced pain, decreased erythema, prevented the formation of new lesions, and healed skin faster than did placebo. The duration of viral shedding was also significantly shorter in acyclovir recipients (2 days versus 5 days). However, 6(35%) of 17 acyclovir recipients had recurrence of pain after the drug was discontinued, and acyclovir did not appear to affect post-herpetic neuralgia. Acyclovir therapy was associated with a transient rise in serum creatinine levels, and may have been related to nausea and vomiting. Intravenous acyclovir was effective therapy for acute herpes zoster but the ideal treatment regimen might be a lower daily dose given for a longer period.

Acute Disease↗

Survival of influenza viruses on environmental surfaces.

To investigate the transmission of influenza viruses via hands and environmental surfaces, the survival of laboratory-grown influenza A and influenza B viruses on various surfaces was studied. Both influenza A and B viruses survived for 24-48 hr on hard, nonporous surfaces such as stainless steel and plastic but survived for less than 8-12 hr on cloth, paper, and tissues. Measurable quantities of influenza A virus were transferred from stainless steel surfaces to hands for 24 hr and from tissues to hands for up to 15 min. Virus survived on hands for up to 5 min after transfer from the environmental surfaces. These observations suggest that the transmission of virus from donors who are shedding large amounts could occur for 2-8 hr via stainless steel surfaces and for a few minutes via paper tissues. Thus, under conditions of heavy environmental contamination, the transmission of influenza virus via fomites may be possible.

Gossypium↗